
For me, the right approach is not to oppose innovative medicines versus generics as I believe there is a symbiosis between the two. This symbiosis allows innovators to utilize their patent, and generics to help expand access in the market.
Tags:
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
See our Cookie Privacy Policy Here